"The OPUS-1 study aims to replicate the positive results observed in the Phase 2 dry eye trial, which demonstrated increases in tear production as early as 2 weeks, an improvement in corneal staining, and better visual-functional outcomes in the SAR 1118 treatment groups compared to placebo," said Charles Semba, MD, Chief Medical Officer. "Initiating patient enrollment in our Phase 3 trial is a significant milestone for SARcode Bioscience as we continue to progress towards our goal of making this therapy commercially available to millions of dry eye sufferers."
"Dry eye is an extremely common and significant problem encountered by eye care professionals," commented Edward Holland, MD, a cornea specialist from the Cincinnati Eye Institute and consultant to SARcode Bioscience. "It is exciting to see this new molecular entity, which was specifically designed for ocular use, enter pivotal trials. If the Phase 3 program is successful, this novel therapy will provide a much needed treatment option that not only alleviates the symptoms of dry eye, but also improves visual-related quality-of-life for patients suffering from this disease."
SARcode Bioscience anticipates completion of the OPUS-1 study and topline data in mid-year 2012.
Source: SARcode Bioscience, Inc.